340bemployed.org

Your Free Source for 340B News and Commentary

  • Home
  • About Us
  • Employers
  • Job Seekers
  • Advertise
  • 340B Health

Senator Slams CMS Response to Questions About EpiPen


 

Print Article

January 26, 2017—Sen. Chuck Grassley (R-Iowa) is ramping up pressure on the Centers for Medicare and Medicaid Services to hand over documents about Mylan Pharmaceuticals’ misclassification of EpiPen as a generic drug and subsequent underpayment of Medicaid rebates. [ms-protect-content id=”2799″]

“We need records,” the senator wrote to CMS Acting Administrator Patrick Conway on Jan. 19. “Provide us with records.  If this is not plain, just talk with my staff and they will be very specific.”

Senator Grassley complained in the letter to Conway about former Acting Administrator’s Andrew Slavitt’s “lackluster and very disappointing” Jan. 18 response to the senator’s previous requests for information about CMS’s communications with Mylan and whether CMS took steps to hold Mylan accountable. Slavitt told Senator Grassley that while CMS believes Mylan misclassified EpiPen and underpaid rebates, CMS lacks statutory authority to compel a manufacturer to reclassify a drug or to issue civil monetary penalties in such a case.

“CMS seems to suggest it lacks the authority to compel drug companies to classify their drugs properly,” Senator Grassley wrote to Conway. “If that’s the case, why didn’t Congress hear this before now? Is the intent to do little or nothing and then when confronted, blame the inaction on a supposed lack of authority? Didn’t CMS have the authority and the obligation to report clear violations of the law to the Justice Department and if so, has it done so in the case of EpiPens and other misclassified drugs?”

“CMS is trying to dodge responsibility for a problem that likely cost the taxpayers hundreds of millions of dollars and damaged Medicaid program integrity,” Senator Grassley wrote. “This won’t stand.”

In December, Senate Finance Committee Chairman Orrin Hatch (R-Utah), then House Energy & Commerce Committee Chairman Fred Upton (R-Mich.), then E&C Health Subcommittee Chair Joseph Pitts (R-Pa.), and E&C Oversight Subcommittee Chair Tim Murphy (R-Pa.) wrote separately to Slavitt about CMS’s handling of the EpiPen matter. Among other questions, they asked whether EpiPen’s misclassification as a generic drug for Medicaid rebate purposes caused hospitals and other healthcare providers in the 340B drug discount program to be overcharged. Slavitt’s response has not come to light.

Hospitals and health systems in the 340B program have asked the U.S. Justice Department to investigate whether Mylan overcharged 340B healthcare providers for EpiPens.


Register – 340B Coalition Winter Conference – February 1-3, 2017 – San Francisco, Calif. [/ms-protect-content]

Follow us on X

340B Health Verified account Follow

340B Health is the leading advocate & resource for hospitals that serve their communities by participating in the 340B drug pricing program. #Protect340B

340BHealth
340bhealth

340B Health

Verified account @340bhealth ·
20h

Social determinants of health — such as housing, income level and more — are important elements of health care and well-being. This week is National #HungerandHomelessnessAwarenessWeek, and #340B hospitals are proven to support higher percentages of patients facing housing and

Reply on Twitter 2122368600593826068 Retweet on Twitter 2122368600593826068 Like on Twitter 2122368600593826068 Twitter 2122368600593826068
340bhealth

340B Health

Verified account @340bhealth ·
15 Nov

The closest hospital for many rural patients can be many miles away, but #340B brings care closer to home. #Becauseof340B, many rural communities can access critical health care treatment without a long trip.

Reply on Twitter 2122074913439948895 Retweet on Twitter 2122074913439948895 Like on Twitter 2122074913439948895 1 Twitter 2122074913439948895
340bhealth

340B Health

Verified account @340bhealth ·
14 Nov

#ICYMI: New on the #340BInsight podcast, as 2027 approaches, the government’s efforts to implement rebates are ramping up, but so are efforts to stop them. 340B Health’s Vice President of Legal and Policy Amanda Nagrotsky offers insight into the rebate battle and describes how

Reply on Twitter 2121651120762195996 Retweet on Twitter 2121651120762195996 Like on Twitter 2121651120762195996 Twitter 2121651120762195996
340bhealth

340B Health

Verified account @340bhealth ·
13 Nov

Research shows #340B hospitals serve higher percentages of disabled Medicare patients than non-340B hospitals. 340B helps all communities receive essential health care services. #Protect340B

Reply on Twitter 2121322454983585970 Retweet on Twitter 2121322454983585970 Like on Twitter 2121322454983585970 Twitter 2121322454983585970
340bhealth

340B Health

Verified account @340bhealth ·
12 Nov

Rural communities experience more challenges in health care — smaller patient populations, workforce shortages, long travel distances, and tighter budgets — which negatively affects the health and well-being of many rural families.

#Becauseof340B, these populations see more

Reply on Twitter 2120913007530459570 Retweet on Twitter 2120913007530459570 Like on Twitter 2120913007530459570 Twitter 2120913007530459570

RSS feed: 340B Informed 340B Informed

  • An In-Depth Look at Total 340B Purchases
  • Ideas for 340B Changes Could Lead to Legislation
  • Help From 340B After a Rare Diagnosis and an Unaffordable Bill

Copyright © 2026 · 340B Health